BACKGROUND AND PURPOSE: Changes in tissue P-glycoprotein (P-gp) activity during pregnancy could affect the pharmacokinetics and thus the efficacy and toxicity of many drugs. Therefore, using positron emission tomography (PET) imaging, we tested whether gestational age affects tissue P-gp activity in the pregnant non-human primate, Macaca nemestrina. EXPERIMENTAL APPROACH: Mid-gestational (day 75 +/- 13, n= 7) and late-gestational (day 150 +/- 10, n= 5) age macaques were imaged after administration of a prototypic P-gp substrate, (11)C-verapamil (13.7-75.4 MBq.kg(-1)), before and during intravenous infusion of a P-gp inhibitor, cyclosporin A (CsA) (12 or 24 mg.kg(-1).h(-1)). Accumulation of radioactivity in the fetal liver served as a reporter of placental P-gp activity. P-gp activity was expressed as CsA-induced percent change in the ratio of the area (0-9 min) under the (11)C-radioactivity concentration-time curve in the tissue (AUC(tissue)) to that in the maternal plasma (AUC(plasma)). KEY RESULTS: The CsA-induced change in AUC(fetal liver)/AUC(maternal)(plasma) of (11)C-radioactivity significantly increased from mid- (35 +/- 25%) to late gestation (125 +/- 66%). Likewise, the CsA-induced change in AUC(maternal brain)/AUC(plasma) increased from mid- (172 +/- 80%) to late gestation (337 +/- 148%). The AUC ratio for the other maternal tissues was not significantly affected. Neither the CsA blood concentrations nor the level of circulating (11)C-verapamil metabolites were significantly affected by gestational age. CONCLUSIONS AND IMPLICATIONS: P-gp activity at the blood-brain barrier and the placental barrier in the macaque increased with gestational age. If replicated in humans, the exposure of the fetus and maternal brain to P-gp substrate drugs, and therefore their efficacy and toxicity, will change during pregnancy.
BACKGROUND AND PURPOSE: Changes in tissue P-glycoprotein (P-gp) activity during pregnancy could affect the pharmacokinetics and thus the efficacy and toxicity of many drugs. Therefore, using positron emission tomography (PET) imaging, we tested whether gestational age affects tissue P-gp activity in the pregnant non-human primate, Macaca nemestrina. EXPERIMENTAL APPROACH: Mid-gestational (day 75 +/- 13, n= 7) and late-gestational (day 150 +/- 10, n= 5) age macaques were imaged after administration of a prototypic P-gp substrate, (11)C-verapamil (13.7-75.4 MBq.kg(-1)), before and during intravenous infusion of a P-gp inhibitor, cyclosporin A (CsA) (12 or 24 mg.kg(-1).h(-1)). Accumulation of radioactivity in the fetal liver served as a reporter of placental P-gp activity. P-gp activity was expressed as CsA-induced percent change in the ratio of the area (0-9 min) under the (11)C-radioactivity concentration-time curve in the tissue (AUC(tissue)) to that in the maternal plasma (AUC(plasma)). KEY RESULTS: The CsA-induced change in AUC(fetal liver)/AUC(maternal)(plasma) of (11)C-radioactivity significantly increased from mid- (35 +/- 25%) to late gestation (125 +/- 66%). Likewise, the CsA-induced change in AUC(maternal brain)/AUC(plasma) increased from mid- (172 +/- 80%) to late gestation (337 +/- 148%). The AUC ratio for the other maternal tissues was not significantly affected. Neither the CsA blood concentrations nor the level of circulating (11)C-verapamil metabolites were significantly affected by gestational age. CONCLUSIONS AND IMPLICATIONS: P-gp activity at the blood-brain barrier and the placental barrier in the macaque increased with gestational age. If replicated in humans, the exposure of the fetus and maternal brain to P-gp substrate drugs, and therefore their efficacy and toxicity, will change during pregnancy.
Authors: Edna F Choo; Daniel Kurnik; Mordechai Muszkat; Tadashi Ohkubo; Sheila D Shay; James N Higginbotham; Hartmut Glaeser; Richard B Kim; Alastair J J Wood; Grant R Wilkinson Journal: J Pharmacol Exp Ther Date: 2006-03-14 Impact factor: 4.030
Authors: Peng Hsiao; Lucy Sasongko; Jeanne M Link; David A Mankoff; Mark Muzi; Ann C Collier; Jashvant D Unadkat Journal: J Pharmacol Exp Ther Date: 2006-01-13 Impact factor: 4.030
Authors: Joost Bart; Antoon T M Willemsen; Harry J M Groen; Winette T A van der Graaf; Theodora D Wegman; Willem Vaalburg; Elisabeth G E de Vries; N Harry Hendrikse Journal: Neuroimage Date: 2003-11 Impact factor: 6.556
Authors: Karen A Kurdziel; Dale O Kiesewetter; Richard E Carson; William C Eckelman; Peter Herscovitch Journal: J Nucl Med Date: 2003-08 Impact factor: 10.057
Authors: Sara Eyal; Francisco S Chung; Mark Muzi; Jeanne M Link; David A Mankoff; Amal Kaddoumi; Finbarr O'Sullivan; Mary F Hebert; Jashvant D Unadkat Journal: J Nucl Med Date: 2009-05 Impact factor: 11.082
Authors: Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See Journal: Am J Cancer Res Date: 2016-08-01 Impact factor: 6.166
Authors: Anand A Joshi; Soniya S Vaidya; Marie V St-Pierre; Andrei M Mikheev; Kelly E Desino; Abner N Nyandege; Kenneth L Audus; Jashvant D Unadkat; Phillip M Gerk Journal: Pharm Res Date: 2016-09-19 Impact factor: 4.200
Authors: Alice Ban Ke; Sara Eyal; Francisco S Chung; Jeanne M Link; David A Mankoff; Mark Muzi; Jashvant D Unadkat Journal: J Nucl Med Date: 2013-01-28 Impact factor: 10.057
Authors: Anand K Deo; Soo Borson; Jeanne M Link; Karen Domino; Janet F Eary; Ban Ke; Todd L Richards; David A Mankoff; Satoshi Minoshima; Finbarr O'Sullivan; Sara Eyal; Peng Hsiao; Ken Maravilla; Jashvant D Unadkat Journal: J Nucl Med Date: 2014-05-19 Impact factor: 11.082